

**YGION Biomedical Awarded Grant from the Austrian Research Promotion Agency to develop Individualized Cancer Immunotherapies**

**Vienna, Austria, 18<sup>th</sup> June 2024** – YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer immunotherapies, today announces further fundraising news with the award of a significant Life Sciences grant from the Austrian Research Promotion Agency (Forschungsförderungsgesellschaft; FFG). This non-dilutive funding will be used over the next 12 months to further development YGION's unique YGNITE™ technology platform and support preclinical development of YGION's lead program, YG-01.

YGION is committed to developing individualized “plug-and-play” cancer vaccines using a proprietary suite of technologies to identify, produce and target the delivery of relevant peptide neoantigens resulting in safe, exceptionally potent, and precise targeted activation of the patient's immune system.

“With this support from the FFG, we will take an important step forward in further developing our differentiated neoantigen immunotherapy platform” said Dr. Wolfgang Fischl, Chief Executive Officer of YGION. “The FFG is the leading public funding agency for translational research in Austria and we are grateful to have this support to undertake fundamental research and development of our lead program YG-01, ultimately enabling us to demonstrate its potential in clinical testing. This will be a critical step in YGION's efforts to improve cancer patient's treatment and quality of life.”

This grant is a follow up to YGION's recent announcement of a €15 million Series A financing round from an Austrian private trust. This competitive grant is awarded to life science companies to support the research and development for innovative healthcare products in Austria.

**About YGION Biomedical**

*YGION Biomedical is a private preclinical stage biopharmaceutical company located in Vienna, Austria committed to realizing individualized immunotherapies against cancer. YGION's YGNITE™ platform combines next generation sequencing, bioinformatics and the proprietary CARGONAUT™ vaccine platform to deliver neoepitope peptide vaccines tailored for each tumor and each patient. For more information, visit [www.ygion.bio](http://www.ygion.bio)*

*The FFG is the central national funding organisation and strengthens Austria's innovative strength. This project is funded by the FFG. [www.ffg.at](http://www.ffg.at)*

**Contact**

Sophie Zettl Ph.D.  
Chief Business Officer, YGION Biomedical GmbH  
[sophie.zettl@ygion.bio](mailto:sophie.zettl@ygion.bio)  
+43 660 573 1746

